Studies to validate novel inhibitors of TYK2 kinase as anti-cancer therapeutics

TYK2酶已被证明是一种罕见类型的白血病T-ALL的关键治疗靶点，这种白血病主要影响年轻人。Sareum发现了一系列新的TYK2选择性抑制剂，并表明它们可以通过引起程序性细胞死亡来阻止T-ALL细胞增殖。这项可行性研究的目的是评估更多化合物对其他T-ALL细胞系的作用，并对T-ALL和TYK2之间的生物学联系有更广泛的了解。如果该项目取得成功，它将保证进一步投资于全面的先导优化计划，以开发用于患者临床试验的候选分子。

The enzyme TYK2 has been shown to be a key therapeutic target in a rare type of leukaemia, T-ALL, which predominantly affects young adults. Sareum has discovered a novel series of selective inhibitors of TYK2, and have shown that they can prevent T-ALL cells from proliferating by causing programmed cell death. The aim of this feasibility study is to assess more compounds against additional T-ALL cell lines and to develop a broader understanding of the biology connecting T-ALL and TYK2. If the project is successful it would warrant further investment in a full lead optimisation programme to develop candidate molecules for clinical trials in patients.